FindTrial
Sign In

IMM01

DRUG6 trials

Sponsors

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Conditions

Acute Myeloid LeukemiaAdvanced Solid TumorsChronic Myelomonocytic LeukemiaClassic Hodgkin LymphomaHematologic MalignancyMyelodysplastic SyndromesSolid Tumor

Phase 1

A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
NCT05140811
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.Acute Myeloid Leukemia, Myelodysplastic Syndromes
Start: 2022-01-05End: 2024-03-01Target: 126Updated: 2023-05-24
Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas
NCT05833984
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.Classic Hodgkin Lymphoma, Solid Tumor
Start: 2022-05-17End: 2024-11-20Target: 309Updated: 2023-04-27
Exploratory Study of IMM01 for Injection in the Treatment of Refractory or Recurrent Hematologic Malignancy
TerminatedNCT05860075
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.Hematologic Malignancy
Start: 2019-11-19End: 2022-10-26Updated: 2023-05-16
A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors
Not yet recruitingNCT07170787
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.Advanced Solid Tumors
Start: 2025-10-15End: 2029-07-31Target: 104Updated: 2025-09-12

Phase 3

A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma
Not yet recruitingNCT06465446
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.Classic Hodgkin Lymphoma
Start: 2024-06-30End: 2029-07-31Target: 202Updated: 2024-06-24
IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)
RecruitingNCT06647862
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.Chronic Myelomonocytic Leukemia
Start: 2024-11-11End: 2029-10-24Target: 170Updated: 2025-11-25

Related Papers

Updated results of a phase 2 study: Timdarpacept (IMM01) combined with azacitidine (AZA) as the first-line treatment in adults with chronic myelomonocytic leukemia (CMML).
Journal of Clinical Oncology2025-05-28
Updated efficacy and safety results from the phase 2 study of timdarpacept in combination with tislelizumab in patients with classical Hodgkin lymphoma for whom prior anti–PD-1 therapy failed.
Journal of Clinical Oncology2025-05-28
Latest results of a phase 2 study of IMM01 combined with azacitidine (AZA) as the first-line treatment in adults with higher risk myelodysplastic syndromes (MDS).
Journal of Clinical Oncology2024-06-011 citations
Timdarpacept (IMM01) in combination with tislelizumab in prior anti-PD-1 failed classical Hodgkin lymphoma: An open label, multicenter, phase II study (IMM01-04) evaluating safety as well as preliminary anti-tumor activity.
Journal of Clinical Oncology2024-06-011 citations
Preliminary Results of a Phase 2 Study of IMM01 Combined with Azacitidine (AZA) As the First-Line Treatment in Adult Patients with Higher Risk Myelodysplastic Syndromes (MDS)
Blood2023-11-029 citations
Preliminary Results of a Phase 2 Study of IMM01 Combined with Azacitidine (AZA) As the First-Line Treatment in Adult Patients with Chronic Myelomonocytic Leukemia (CMML)
Blood2023-11-025 citations